2025-01-012025-12-312025-12-31false12749468KURK BIOSCIENCES LTD.2026-09-1110320falseiso4217:GBPxbrli:pure127494682024-12-31127494682025-12-31127494682025-01-012025-12-31127494682023-12-31127494682024-12-31127494682024-01-012024-12-3112749468bus:SmallEntities2025-01-012025-12-3112749468bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3112749468bus:FullAccounts2025-01-012025-12-3112749468bus:PrivateLimitedCompanyLtd2025-01-012025-12-3112749468core:WithinOneYear2025-12-3112749468core:AfterOneYear2025-12-3112749468core:WithinOneYear2024-12-3112749468core:AfterOneYear2024-12-311274946812025-01-012025-12-3112749468core:ShareCapital2025-12-3112749468core:SharePremium2025-12-3112749468core:RevaluationReserve2025-12-3112749468core:OtherReservesSubtotal2025-12-3112749468core:RetainedEarningsAccumulatedLosses2025-12-3112749468core:ShareCapital2024-12-3112749468core:SharePremium2024-12-3112749468core:RevaluationReserve2024-12-3112749468core:OtherReservesSubtotal2024-12-3112749468core:RetainedEarningsAccumulatedLosses2024-12-3112749468core:LandBuildings2025-12-3112749468core:PlantMachinery2025-12-3112749468core:Vehicles2025-12-3112749468core:FurnitureFittings2025-12-3112749468core:OfficeEquipment2025-12-3112749468core:NetGoodwill2025-12-3112749468core:IntangibleAssetsOtherThanGoodwill2025-12-3112749468core:ListedExchangeTraded2025-12-3112749468core:UnlistedNon-exchangeTraded2025-12-3112749468core:LandBuildings2024-12-3112749468core:PlantMachinery2024-12-3112749468core:Vehicles2024-12-3112749468core:FurnitureFittings2024-12-3112749468core:OfficeEquipment2024-12-3112749468core:NetGoodwill2024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-12-3112749468core:ListedExchangeTraded2024-12-3112749468core:UnlistedNon-exchangeTraded2024-12-3112749468core:LandBuildings2025-01-012025-12-3112749468core:PlantMachinery2025-01-012025-12-3112749468core:Vehicles2025-01-012025-12-3112749468core:FurnitureFittings2025-01-012025-12-3112749468core:OfficeEquipment2025-01-012025-12-3112749468core:NetGoodwill2025-01-012025-12-3112749468core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3112749468core:ListedExchangeTraded2025-01-012025-12-3112749468core:UnlistedNon-exchangeTraded2025-01-012025-12-3112749468core:MoreThanFiveYears2025-01-012025-12-3112749468core:Non-currentFinancialInstruments2025-12-3112749468core:Non-currentFinancialInstruments2024-12-3112749468dpl:CostSales2025-01-012025-12-3112749468dpl:DistributionCosts2025-01-012025-12-3112749468core:LandBuildings2025-01-012025-12-3112749468core:PlantMachinery2025-01-012025-12-3112749468core:Vehicles2025-01-012025-12-3112749468core:FurnitureFittings2025-01-012025-12-3112749468core:OfficeEquipment2025-01-012025-12-3112749468dpl:AdministrativeExpenses2025-01-012025-12-3112749468core:NetGoodwill2025-01-012025-12-3112749468core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3112749468dpl:GroupUndertakings2025-01-012025-12-3112749468dpl:ParticipatingInterests2025-01-012025-12-3112749468dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3112749468core:ListedExchangeTraded2025-01-012025-12-3112749468dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3112749468core:UnlistedNon-exchangeTraded2025-01-012025-12-3112749468dpl:CostSales2024-01-012024-12-3112749468dpl:DistributionCosts2024-01-012024-12-3112749468core:LandBuildings2024-01-012024-12-3112749468core:PlantMachinery2024-01-012024-12-3112749468core:Vehicles2024-01-012024-12-3112749468core:FurnitureFittings2024-01-012024-12-3112749468core:OfficeEquipment2024-01-012024-12-3112749468dpl:AdministrativeExpenses2024-01-012024-12-3112749468core:NetGoodwill2024-01-012024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112749468dpl:GroupUndertakings2024-01-012024-12-3112749468dpl:ParticipatingInterests2024-01-012024-12-3112749468dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3112749468core:ListedExchangeTraded2024-01-012024-12-3112749468dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3112749468core:UnlistedNon-exchangeTraded2024-01-012024-12-3112749468core:NetGoodwill2025-12-3112749468core:IntangibleAssetsOtherThanGoodwill2025-12-3112749468core:LandBuildings2025-12-3112749468core:PlantMachinery2025-12-3112749468core:Vehicles2025-12-3112749468core:FurnitureFittings2025-12-3112749468core:OfficeEquipment2025-12-3112749468core:AfterOneYear2025-12-3112749468core:WithinOneYear2025-12-3112749468core:ListedExchangeTraded2025-12-3112749468core:UnlistedNon-exchangeTraded2025-12-3112749468core:ShareCapital2025-12-3112749468core:SharePremium2025-12-3112749468core:RevaluationReserve2025-12-3112749468core:OtherReservesSubtotal2025-12-3112749468core:RetainedEarningsAccumulatedLosses2025-12-3112749468core:NetGoodwill2024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-12-3112749468core:LandBuildings2024-12-3112749468core:PlantMachinery2024-12-3112749468core:Vehicles2024-12-3112749468core:FurnitureFittings2024-12-3112749468core:OfficeEquipment2024-12-3112749468core:AfterOneYear2024-12-3112749468core:WithinOneYear2024-12-3112749468core:ListedExchangeTraded2024-12-3112749468core:UnlistedNon-exchangeTraded2024-12-3112749468core:ShareCapital2024-12-3112749468core:SharePremium2024-12-3112749468core:RevaluationReserve2024-12-3112749468core:OtherReservesSubtotal2024-12-3112749468core:RetainedEarningsAccumulatedLosses2024-12-3112749468core:NetGoodwill2023-12-3112749468core:IntangibleAssetsOtherThanGoodwill2023-12-3112749468core:LandBuildings2023-12-3112749468core:PlantMachinery2023-12-3112749468core:Vehicles2023-12-3112749468core:FurnitureFittings2023-12-3112749468core:OfficeEquipment2023-12-3112749468core:AfterOneYear2023-12-3112749468core:WithinOneYear2023-12-3112749468core:ListedExchangeTraded2023-12-3112749468core:UnlistedNon-exchangeTraded2023-12-3112749468core:ShareCapital2023-12-3112749468core:SharePremium2023-12-3112749468core:RevaluationReserve2023-12-3112749468core:OtherReservesSubtotal2023-12-3112749468core:RetainedEarningsAccumulatedLosses2023-12-3112749468core:AfterOneYear2025-01-012025-12-3112749468core:WithinOneYear2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3112749468bus:Director12025-01-012025-12-3112749468core:FurnitureFittingsToolsEquipment2024-12-3112749468core:FurnitureFittingsToolsEquipment2025-01-012025-12-3112749468core:FurnitureFittingsToolsEquipment2025-12-31

KURK BIOSCIENCES LTD.

(formerly 6 DEGREES BIOSCIENCE UK LTD)

Registered Number
12749468
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2025

KURK BIOSCIENCES LTD.
Company Information
for the year from 1 January 2025 to 31 December 2025

Director

Trent Gordon Scanlen

Registered Address

Unit 12 Mill Farm Business Park
Millfield Road
Hounslow
TW4 5PY

Registered Number

12749468 (England and Wales)
KURK BIOSCIENCES LTD.
Balance Sheet as at
31 December 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3386446
Tangible assets476,39791,066
76,78391,512
Current assets
Stocks5288,368188,213
Debtors65,26559,181
Cash at bank and on hand8,9634,799
362,596252,193
Creditors amounts falling due within one year6(2,388,912)(1,682,151)
Net current assets (liabilities)(2,026,316)(1,429,958)
Total assets less current liabilities(1,949,533)(1,338,446)
Net assets(1,949,533)(1,338,446)
Capital and reserves
Called up share capital11
Profit and loss account(1,949,534)(1,338,447)
Shareholders' funds(1,949,533)(1,338,446)
The financial statements were approved and authorised for issue by the Director on 11 September 2026, and are signed on its behalf by:
Trent Gordon Scanlen
Director
Registered Company No. 12749468
KURK BIOSCIENCES LTD.
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year32
3.Intangible assets

Other

Total

££
Cost or valuation
At 01 January 25600600
At 31 December 25600600
Amortisation and impairment
At 01 January 25154154
Charge for year6060
At 31 December 25214214
Net book value
At 31 December 25386386
At 31 December 24446446
4.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 January 2569,44967,7894,122141,360
Disposals-(7,217)-(7,217)
At 31 December 2569,44960,5724,122134,143
Depreciation and impairment
At 01 January 2527,12322,73443750,294
Charge for year6,9457,217-14,162
On disposals-(6,710)-(6,710)
At 31 December 2534,06823,24143757,746
Net book value
At 31 December 2535,38137,3313,68576,397
At 31 December 2442,32645,0553,68591,066
5.Stocks

2025

2024

££
Finished goods288,368188,213
Total288,368188,213
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables92,66465,536
Bank borrowings and overdrafts187,749-
Amounts owed to related parties2,094,6801,444,869
Taxation and social security3,858151,557
Other creditors1,7441,341
Accrued liabilities and deferred income8,21718,848
Total2,388,9121,682,151
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.